share_log

復宏漢霖:自願公告 - HLX53(抗TIGIT的Fc融合蛋白)聯合漢斯狀(斯魯利單抗注射液) 及漢貝泰(貝伐珠單抗注射液)一線治療局部晚期或轉移性肝細胞癌的 臨床試驗申請獲國家藥品監督管理局批准

HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE CLINICAL TRIAL OF HLX53 (ANTI-TIGIT FC FUSION PROTEIN) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) AND HANBEITAI (BEVACIZUMAB INJECTION) FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC

Hong Kong Stock Exchange ·  Apr 17 04:56
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more